Pharmaceuticals, Biotechnology and Life Sciences
Mereo BioPharma Group, a clinical stage, biopharmaceutical company focused on rare and specialty diseases, has completed patient enrolment in the AETHER, multi-centre, double-blind, placebo-controlled Phase 2 dose-ranging study of acumapimod (BCT-197), for the treatment of patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
The world needs greater transparency on the pricing of medicines, and an overhaul of some approaches, in order to increase access to life-saving drugs, global health experts said on Thursday.
AstraZeneca and its subsidiary MedImmune, have reported positive results for the Phase III PACIFIC trial, a randomised, double-blinded, placebo-controlled multi-centre trial of Imfinzi (durvalumab) as sequential treatment in patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy.
Stada Arzneimittel has reported adjusted net income of €53.3 million for the first quarter of 2017 which is 33% increase compared to last years net income of €40.1 million.
Have you ever found yourself craving a steak or a burger? The brain controls our feelings of hunger and also determines the types of nutrients we should be seeking out. Not much is understood about the brain’s regulation of nutrient-specific hunger, but in a new study published in Science, researchers identified the brain cells in fruit flies that regulate protein hunger and were able to control those cells, affecting what the animals ate. The study, was funded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.
Catalyst Pharmaceuticals has reported a GAAP net loss of $4.9 million for first quarter of 2017, compared to a GAAP net loss of $5,4 for the same period in 2016.
Leigh Ann Pusey will join Eli Lilly as senior vice president of corporate affairs and communications, effective June 12, 2017. She will be a member of Lilly’s executive committee reporting directly to president and chief executive officer, David A. Ricks.
Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, todayhas reported financial results for the fiscal quarter ended March 31, 2017.
Bristol-Myers Squibb (BMS) and Calithera Biosciences have expanded their existing collaboration to evaluate BMS’s Opdivo in combination with Calithera’s CB-839 in patients with non-small cell lung cancer (NSCLC) and melanoma.
Allergan announced that it expects to commence an offering of euro-denominated senior unsecured notes in multiple tranches in the coming weeks.